Applied Symbiotic Intelligence
Your next breakthrough is already published. No one has connected the dots.
We produce original scientific intelligence from your published research — novel hypotheses with full evidence provenance, delivered in days, not months.
The problem

The answers to your hardest scientific questions already exist — scattered across journals, disciplines, and species boundaries that no single researcher reads together. A gene editing lab publishes findings that the immunotherapy team across the hall would recognize as transformative. Two of your own published papers contain a contradiction with millions of dollars in implications. Nobody sees it because nobody holds all the pieces at once.

This fragmentation has a price. Failed trials that published data could have predicted. Research directions that dead-end years later. And discoveries that sit dormant — not because the science failed, but because it never found the right context.

$7.7B
Terminated assets / yr
67 wks
Avg. lit review
80%+
Unused R&D data
$236B
Patent cliff risk
What changes when you work with us
Research Institutions
Your labs publish extraordinary science — but separate pipelines mean connections go unseen. We surface cross-lab synergies, hidden contradictions, and platform opportunities hiding between your own papers.
Tens of millions in cost-avoidance · 14 days
Pharma & Biotech R&D
We synthesize across domains — immunology, pharmacology, tumor biology, clinical oncology — and surface interactions your trial designs may not account for. Companion diagnostic white space. Testable predictions from existing tissue.
10+ testable predictions, half requiring no new patients · 2–4 weeks
Clinical & Translational
Published pharmacology data contains corrections that could redirect your program — receptor-level inversions, temporal factors that flip risk-benefit profiles, stratification signals in existing datasets.
Seed paper to 8 intervention protocols · 48 hours
What happened when experts saw the work
Dean of Pharmacy, Major Research University
Reviewed our analysis of a single paper of hers. With zero prior domain exposure, our methodology produced in 36 hours the scientific directions her lab has been pursuing in unpublished research for six years.
“Actively pursuing most of what you uncovered now in the laboratory.”
UCLA Oncologist
Reviewed our analysis of her own seven-year-old published research — the person on Earth best positioned to judge accuracy.
37 min to first response → co-author in 48 hrs → university publication pipeline in 3 days
Dean of Veterinary Medicine
Reviewed cross-species findings. Championed the work across disciplines and connected us to researchers at multiple institutions.
“You’re not only changing veterinary medicine, you’re changing our world.”
Venture Capital — AI for Good
Evaluates hundreds of AI companies for transformative social impact. Compared the work to Palantir twice unprompted. Brokered introductions to a major research institution in the same conversation.
“I have not seen that out there.”
0
Findings with provenance
11+
Scientific domains
0
Patent-pending filings
0
Adversarial self-corrections
“Actively pursuing most of what you uncovered now in the laboratory.”
Dean of Pharmacy, Major Research University
After reviewing a single-paper analysis produced in 36 hours — matching 6 years of unpublished lab directions
Why nobody else does this
Billions of dollars have been spent building AI molecules. No AI-discovered drug has reached Phase 3. Those companies built answers. We sell the questions — and the questions are worth more.

Everyone has AI. AI is infrastructure, like electricity. What ASI does is not “use AI better.” We operate upstream — at the level of what to ask, how to verify, and when to trust the answer. The methodology is the product. The intelligence speaks for itself.

Four independent competitive analyses found no company selling what we sell — packaged novel scientific hypotheses with evidence provenance at consulting-tier pricing. The space appears vacant.

Our methodology stress-tests its own conclusions before delivery. 421 adversarial challenges across our intelligence corpus — errors caught, overclaims corrected, scope limitations documented. We deliver hypotheses with their stress-tests attached.
How to start
1
Discovery Pilot We analyze a small set of your published papers and show you what we find. If the intelligence is valuable, we discuss a full engagement. You see the quality before any commitment. Structured briefing with findings, evidence chains, and identified opportunities · 1–2 weeks Engagements begin at five figures
2
Intelligence Product A comprehensive cross-domain analysis — like our gene therapy package (8 papers, 232 findings, 5 actionable connections, $8–23M cost avoidance, 14 days) or our immunotherapy analysis (50+ publications, 10 testable predictions, 5 requiring no new patients). Full intelligence package — findings, evidence provenance, testable hypotheses, strategic implications · 2–4 weeks
3
Intelligence Partnership Ongoing cross-domain sight across your portfolio. Continuous intelligence as your programs evolve, new papers publish, and the competitive landscape shifts. Our methodology compounds — each engagement builds on everything before it. Recurring intelligence briefings, priority analysis of new publications, direct analytical access
Who we are

Three co-founders. Zero external funding. 128 days of focused execution. Seven patent-pending applications across the full methodology. The capital efficiency is the proof — three people produced intelligence that $500M companies could not.

Ryan Gruzen
Co-Founder & CEO
Cross-domain intelligence production and client relationships. Founded Pet Portal AI (Plug and Play Accelerator). Leads all analytical operations and scientific synthesis.
LinkedIn →
Harold Lee
Co-Founder & CTO
Technical architecture and AI systems. MBA. U.S. patent holder. Former CEO of Music Prodigy (reached #1 in 20 countries). Builds the infrastructure that powers our methodology.
LinkedIn →
Devin Pellegrino
Co-Founder & Chief Architect
Knowledge systems and neuromodulation. Georgia Institute of Technology. Designs the analytical framework architecture. Background in medical device implementation and neurotechnology.
LinkedIn →

Your published papers already contain breakthroughs nobody has connected.

We find them. Every finding traced to its source. Every hypothesis stress-tested before you see it. Send us your hardest question — or just your published papers — and we’ll show you what we find.

Patent-pending methodology · Every claim traced to source